We are live on ! Find out more

Clene

CLNN

Market cap $51.7M

3.98 USD

+0.12

3.11%

At close Updated Sep 17, 1:22 PM EDT

1 day

3.11%

5 days

6.99%

1 month

-5.24%

3 months

-32.88%

6 months

-35.07%

Year to date

-31.02%

1 year

-35.49%

5 years

-97.53%

10 years

-97.94%

About: Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Employees: 79

Consumer Staples Packaged Foods

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 12.5%

Neutral 87.5%

Negative 0%

Clene Announces $4 Million Registered Direct Offering

Investment led by Clene's Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene's Chief Executive Officer and other existing shareholders $4 million registered direct offering priced at market under Nasdaq rules Proceeds are expected to be sufficient to fund the Company to mid-first quarter 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the pricing of a registered direct offering of 1,219,513 shares at a purchase price of $3.28 per share to existing shareholders, including insiders, with total gross proceeds of $4 million.

Clene Announces $4 Million Registered Direct Offering

Clene to Present at Upcoming September Investor Conferences

SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C.

Clene to Present at Upcoming September Investor Conferences

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses

Clene NASDAQ: CLNN is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses requested by the U.S. Food and Drug Administration, President and CEO Rob Etherington said in an interview.

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses

Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation Details Date: August 19, 2026 Time of Presentation: 3:10 p.m.

Clene to Present at the Emerging Growth Conference

Zacks Investment Research

Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates

Clene Inc. (CLNN) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.78 per share a year ago.

Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-treated patients whose NfL declined or stabilized SALT LAKE CITY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced its second quarter 2026 financial results and provided recent updates on its CNM-Au8 programs. “We plan to submit our new drug application (NDA) for CNM-Au8 under the accelerated approval pathway for patients with ALS and believe the evidence connecting the magnitude of NfL reduction to clinical benefit data we have generated since our last FDA meeting will be critical for a successful review,” said Rob Etherington, President and CEO of Clene.

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS

Clene NASDAQ: CLNN said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of meetings with the U.S. Food and Drug Administration.

Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS

Clene to Present at The Canaccord 46th Annual Growth Conference

SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 46th Annual Growth Conference and host 1x1 investor meetings.

Clene to Present at The Canaccord 46th Annual Growth Conference

Zacks Investment Research

Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Clene (CLNN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks Investment Research

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

Clene Inc. (CLNN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.5 per share a year ago.

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

See News Rankings

Price charts implemented using Lightweight Charts™